Anti-VEGF therapy may revolutionize ROP treatment

A single intravitreal injection of an anti-VEGF agent in babies with retinopathy of prematurity

induces regression of pathological neovascularization and also promotes resumption of

physiological vascularization of the retina, Tim U Krohne MD of the University of Bonn Eye

Clinic told the World Society of Paediatric Ophthalmology & Strabismus. As such, it could

eliminate the need to ablate avascular retina tissue and has the potential to revolutionize ROP

treatment.

However, several issues must be addressed before anti-VEGF is adopted, Dr Krohne said. These

include establishing the smallest effective dose and assessing safety with particular attention to

systemic side effects. Injection sight is also an issue since premature infant eyes are very small.

ESCRS celebrates milestones with pioneers in IOLs, LASIK, femtosecond lasers, and corneal transplantation.

From YOs to families, the ESCRS Annual Meeting embraces full participation through inclusivity.

Watching out for obstacles and opportunities

Empowering patient participation fosters continuous innovation in cataract surgery.

Practice management workshop focuses on financial operations and AI business applications.

USAID closure leads retreat in development assistance.

FS-LASIK has more of a track record, but KLEx offers advantages.

Commercial offerings may save time, improve practice and research.

Randomised controlled clinical trial results provide evidence-based guidance.